Natural killer and lymphokine activated killer cell functions in Hodgkin's disease

Rajaram, Nirmala; Tatake, Revati J.; Advani, SH; Gangal, S. G.

doi:10.1038/bjc.1990.261

Cited by 12 publications

(6 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some earlier studies, focusing on enumeration of NK cells, indicated a decrease in their number in active states of HD (Berenyi et al , 1996). Unlike our and previous findings, Rajaram et al (1990) reported normal NK‐cell activity for patients with active HD, except for those with histological type of lymphocyte depletion and clinical stage IV. Nevertheless, the found impairment in NK‐cell function is supported by the findings of alterations of NK‐cell subsets in HD patients (Macklis et al , 1993) and reported increased serum CD8 soluble antigen levels indicative of suppressive T‐cell function (Grinfors et al , 1992).…”

Section: Discussioncontrasting

confidence: 99%

The difference in NK‐cell activity between patients with non‐Hodgkin's lymphomas and Hodgkin's disease

et al. 1999

View full text Add to dashboard Cite

Summary. Natural killer (NK) cells play an important role in immune surveillance against malignant diseases. Considering the lymphoid origin of malignant lymphomas, as well as scarce data concerning NK-cell function in these neoplasms, we evaluated NK-cell activity in 49 patients with nonHodgkin's lymphomas (NHL) and 47 patients with Hodgkin's disease (HD), prior to therapy. Using the recommended International Working Formulation and the Ann Arbor staging system for classification of lymphomas we found, by the LDH release cytotoxicity assay, that decreased NK-cell activity (P < 0·05) in NHL patients was essentially related to unfavourable histology (13 indolent lymphomas, 25 intermediate and 11 very aggressive lymphomas were included), but that within these categories clinical stage of the disease also contributed to the degree of NK-cell dysfunction. In contrast, in HD, NK-cell activity was persistently decreased (P < 0·05), compared to controls, irrespective of histological type and clinical stage. It is of interest also that the most profound NK-cell dysfunction that is present and persistent from the onset of HD, and which appears in very aggressive NHL was associated with the phenomenon of increased spontaneous lactate acid dehydrogenase (LDH) release activity from the separated PBMC of these patients. The difference in the level of NK-cell impairment between patients with various histological grades of malignancy in NHL and HD suggests different initial participation of innate immune reactions in these diseases.

show abstract

Section: Discussioncontrasting

confidence: 99%

The difference in NK‐cell activity between patients with non‐Hodgkin's lymphomas and Hodgkin's disease

et al. 1999

View full text Add to dashboard Cite

show abstract

“…In untreated patients with Hodgkin's disease differing levels of NK cytotoxicity have been reported (Al Sam et al 1982;Gupta & Fernandes 1982;Frydecka et al 1985;Rajaram et al 1990). Our results showed an increase in NK cell activity in untreated patients compared with controls, in accordance with the results of Al Sam et al (1982) activity of the 11 patients studied before and after treatment was significantly increased after treatment (P = 0.016).…”

Section: Discussionmentioning

confidence: 99%

“…A number of immunological defects have been described during the course of Hodgkin's disease (HD) and as a result of its treatment. Some studies have shown normal NK cell activity pretreatment (Gupta & Fernandes 1982;Rajaram et al 1990), others have reported a reduced activity in untreated patients and in patients in the active phase of the disease during treatment (Frydecka 1985), while others have reported an increase in NK activity in the spleen of untreated patients (Al Sam et al 1982) and in the peripheral blood of HD patients following treatment (Macklis et al 1992;Macklis et al 1993). Lymphoid irradiation results in long-term increases in the number of NK cells (Macklis et al 1992) which appears to be a generalized expansion of the entire NK cell compartment rather than an increase in any specific NK cell subset (Macklis et al 1993).…”

Section: Introductionmentioning

confidence: 99%

Natural killer cell activity in Hodgkin's disease patients undergoing radiation therapy or chemotherapy and radiation therapy

Pinel

Esteves²,

Rumjanek

1998

Clinical &Amp; Laboratory Haematology

View full text Add to dashboard Cite

Natural killer (NK) cell activity in peripheral blood mononuclear cells (PBMCs) from patients with Hodgkin's disease was studied using 4 h 51Cr release assay and K562 cells as sensitive targets. PBMCs were obtained from 15 previously untreated patients at different stages of their disease. PBMCs were also obtained from 46 patients treated by radiation therapy or combined chemotherapy and radiation therapy. Twenty healthy age-matched volunteer donors were used as controls to the treated patients. For these normal donors the mean cytotoxicity was 24.8 +/- 5.67% at a 100:1 effector-target cell ratio; and 43.7 +/- 12.1% for the treated cancer patients. Fifteen healthy age-matched volunteer donors were used as controls to the untreated patients. The mean cytotoxicity for these normal donors was 20.8 +/- 3.61% at a 100:1 effector-target cell ratio; and 37.6 +/- 6.65% for the previously untreated cancer patients. The mean cytotoxicity for all 35 normal donors was 23.1 +/- 5.22% at a 100:1 effector-target cell ratio. Most treated patients (93.5%) had a complete response to therapy and a significant difference was found between the mean cytotoxicity of the whole group (46 treated patients), compared with controls (P < 0.001). A significant difference (P < 0.05) was also observed when the same 11 patients were studied before and after treatment.

show abstract

“…Therefore it could be envisaged that LAK cells would also contribute to sIL-2R by shedding the receptors in which case their effector function would be jeopardized. However, we have found that in HD, the NK and LAK activities of the PBL were within the normal range or higher (Rajaram et al, 1990). In order to correlate high levels of sIL-2R with NK/LAK activity in HD, assessment of the 3 parameters need to be performed in the same patients.…”

Section: Lymphocytes From Healthy Donorsmentioning

confidence: 92%

Analysis of regulation of T‐cell responses by soluble inhibitory factors from the sera of patients with Hodgkin's disease

Damle¹,

Advani

Gangal³

1992

Intl Journal of Cancer

View full text Add to dashboard Cite

Soluble inhibitory factors (SIF) have been demonstrated in the sera of cancer patients, which interfere with the T-cell activation process. We have shown that the major contributory factor to the inhibitory effect of sera from patients with Hodgkin's disease (HD) could be the soluble form of Interleukin-2 receptors (sIL-2R). The parameters studied to show the presence of SIF include (i) inhibiton of mitogen-induced proliferation; (ii) status of high- and low-affinity IL-2R; and (iii) internalization of IL-2-IL-2R complex, by lymphocytes from healthy donors activated with mitogen in presence of HD sera. Parameters studied to show the inhibitory role of sIL2R include (i) quantitation of sIL-2R in HD sera; (ii) effect of high-sIL-2R-containing sera on mitogen-induced proliferation and detection of IL-2 in activated lymphocyte culture supernatants; (iii) effect of exogenous IL-2 supplementation; and (iv) abrogation of inhibitory activity of sIL-2R-containing sera after passing them through IL-2 affinity columns. Our results show that 6/23 HD sera tested had high inhibitory activity (greater than 50% inhibition of mitogen-induced proliferation). The SIF did not affect expression of high- and low-affinity IL-2 receptors, or internalization of the complex by activated lymphocytes. Ten of the 15 sera tested showed significantly high levels of sIL-2R. Pooled sera with high sIL-2R content inhibited mitogen-induced proliferation of normal lymphocytes with a concomitant reduction in IL-2 activity in the lymphocyte culture supernatants. When supplemented with exogenous IL-2, there was a partial recovery of the inhibitory effect. When sIL-2R containing serum pool was passed on IL-2 affinity columns, the inhibitory effect was reduced. The eluted "sIL-2R" adsorbed on the IL-2 column showed anti-proliferative effect.

show abstract

Natural killer and lymphokine activated killer cell functions in Hodgkin's disease

Cited by 12 publications

References 22 publications

The difference in NK‐cell activity between patients with non‐Hodgkin's lymphomas and Hodgkin's disease

The difference in NK‐cell activity between patients with non‐Hodgkin's lymphomas and Hodgkin's disease

Natural killer cell activity in Hodgkin's disease patients undergoing radiation therapy or chemotherapy and radiation therapy

Analysis of regulation of T‐cell responses by soluble inhibitory factors from the sera of patients with Hodgkin's disease

Contact Info

Product

Resources

About